SIRNA

Oligonucleotide Synthesis, Modification, and Purification Services Market worth $6.53 Billion by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Tuesday, July 5, 2022
GE Healthcare, Integrated DNA Technologies, Medication, Research, NGS, Hospital, COVID-19, Growth, Uridine, Diagnosis, Mass spectrometry, Vaccine, Molecular biology, Lists of diseases, Oligonucleotide, RNA transfection, Integration, CMOS, GMP, Thermo Fisher Scientific, Dharmacon, CAGR, RNA, Mirna, Contract, SNP, Biotechnology, Wuxi, LC, Viral Research and Diagnostic Laboratories, Merck Millipore, University of Sheffield, Sheffield, PCR, Degenerative disease, Nucleotide, CDMO, OEM, Bio-Synthesis, Inc., University, Biochemistry, DNA, Regulus Therapeutics, Medicine, Uridine triphosphate, Agilent Technologies, Fine chemical

Ltd. announces the release of a market assessment report on the " Global Oligonucleotide Synthesis, Modification and Purification Services Market Oligonucleotide Mfg.

Key Points: 
  • Ltd. announces the release of a market assessment report on the " Global Oligonucleotide Synthesis, Modification and Purification Services Market Oligonucleotide Mfg.
  • According to the latest research by InsightAce Analytic, the global oligonucleotide synthesis, modification, and purification services market is valued at US$ 1.56 billion in 2021, and it is expected to reach US$ 6.53 billion by 2030 with a CAGR of 17.50% during a forecast period of 2022-30.
  • Recently, there has been an augmented interest in involving modified oligoribonucleotides in molecular biology, biochemistry, and medicine.
  • However, the high expenses for the purification process, complex manufacturing procedures, oligo-degradation in the generic research, in-house development of oligonucleotides may hinder the growth of the global oligonucleotide synthesis, modification, and purification services market.

Vect-Horus Strengthens its Scientific Advisory Board with the Appointment of Dr. Julia Alterman

Retrieved on: 
Tuesday, March 22, 2022
Medical Devices, Hospitals, Genetics, Clinical Trials, Stem Cells, Other Health, Biotechnology, Pharmaceutical, Health, Oncology, Therapy, Drug development, Pharmacology, Aix-Marseille University, CNS, Biotechnology, Oligonucleotide, Faculty, United States Air Force Scientific Advisory Board, CEO, RNA, Tissue, Technology, CNRS, Organic acid, Sirna Therapeutics, Institute, University of Massachusetts, SAB, University, Pharmaceutical industry, Vaccine

Vect-Horus, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Julia Alterman to its scientific advisory board.

Key Points: 
  • Vect-Horus, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Julia Alterman to its scientific advisory board.
  • Julia received her Ph.D. from UMass Med where she focused on oligonucleotide chemical and structural design and CNS pharmacology.
  • Prior to joining the faculty, Julia spent 7 years in positions at Atalanta Therapeutics, Anchor Therapeutics and Resolvyx Pharmaceuticals.
  • Jamal Temsamani, Director of Drug Development of Vect-Horus commented, We are pleased to welcome Julia Alterman to our Scientific Advisory Board.

Thompson Savannah Makes Debut, Bringing a Contemporary Lifestyle Hotel to Eastern Wharf

Retrieved on: 
Monday, August 2, 2021
Savannah metropolitan area, Savannah, Georgia, Hyatt

SAVANNAH, Ga., Aug. 2, 2021 /PRNewswire/ -- Hyatt Hotels Corporation (NYSE: H) today announced the opening of Thompson Savannah , the brand's first property in Georgia.

Key Points: 
  • SAVANNAH, Ga., Aug. 2, 2021 /PRNewswire/ -- Hyatt Hotels Corporation (NYSE: H) today announced the opening of Thompson Savannah , the brand's first property in Georgia.
  • Set along the banks of the Savannah River, Thompson Savannah, located at the junction of the city's Historic District and its newest neighborhood, Eastern Wharf, is a joint venture development by Regent Partners, Mariner Groupand Cadre.
  • Through thoughtful design that combines historic architectural details and contemporary flair, the hotel honors Savannah's vibrant history and celebrates the local community.
  • Founded in 2001, Thompson Hotels is an award-winning boutique lifestyle hospitality brand with a collection of stunning, dynamic properties.